Irbesartan has a plasma elimination half-life of about 11 to 15 hours, which means a single dose is largely cleared from your bloodstream within roughly three days. That “three days” figure comes from a standard pharmacokinetic rule: after five to six half-lives, a drug’s concentration drops to a negligible level. But real-world clearance depends on more than just the average half-life, and certain genetic, age-related, and drug-interaction factors can stretch that timeline considerably.
How Quickly Irbesartan Reaches Its Peak
After you swallow a standard 150 mg tablet, irbesartan is absorbed through the gut and reaches its highest concentration in the blood within about an hour and a half to two hours. That peak is when the drug is doing the most work blocking angiotensin II receptors and lowering blood pressure. From there, blood levels start to decline as the liver metabolizes the drug and the body gradually eliminates it.
The absorption step is fairly efficient. Irbesartan’s oral bioavailability runs around 60 to 80 percent, meaning a large share of what you swallow actually makes it into systemic circulation. And if you’re wondering whether you need to take it with or without food, the answer is that it doesn’t matter. A study in healthy volunteers found that food had no meaningful effect on either peak concentration or overall drug exposure.
1PubMed. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteersHow the Body Breaks Down Irbesartan
The liver handles almost all of irbesartan’s metabolism, and one enzyme does most of the heavy lifting: CYP2C9. Research using human liver samples showed that blocking CYP2C9 with a known inhibitor nearly shut down irbesartan’s breakdown, while blocking other common liver enzymes had little or no effect. Only lab-grown cells carrying the CYP2C9 gene were able to metabolize irbesartan, confirming that this single enzyme is the primary exit route.
2PubMed. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomesThis matters because anything that interferes with CYP2C9 can slow down how fast your body clears irbesartan, effectively extending the time it stays in your system. The metabolites produced by this process are themselves inactive and are excreted through bile and urine. Less than 3 percent of an irbesartan dose leaves the body unchanged in urine, which is why kidney function plays a surprisingly small role in clearance.
Reaching Steady State With Daily Dosing
Most people take irbesartan once a day. When you do that, the drug doesn’t fully wash out before the next dose arrives, so blood levels build up slightly over the first few days. Studies in both healthy volunteers and patients with liver cirrhosis found that steady-state concentrations were reached within three days of starting daily dosing.
3PubMed. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects4PubMed. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
Importantly, there was no sign of clinically meaningful drug accumulation. That is, the drug doesn’t keep piling up in the body over weeks and months. By day three, what goes in roughly matches what comes out, and blood levels stabilize into a predictable daily pattern of peak and trough. This predictability is part of why irbesartan works well as a once-daily medication: its 11-to-15-hour half-life, combined with how tightly it binds to the AT1 receptor, keeps blood pressure controlled through a full 24-hour dosing interval.
5Current Therapeutic Research. Irbesartan monotherapy in systemic hypertension: An open-label, uncontrolled trialGenetic Differences That Change the Timeline
Because CYP2C9 is irbesartan’s main metabolic pathway, your personal version of the CYP2C9 gene has a direct effect on how long the drug lingers. Not everyone carries the same version. Some people carry variant alleles that produce a slower-working form of the enzyme.
A study in healthy Korean subjects found that people carrying one copy of the CYP2C9*3 variant had half-lives about 1.4 times longer than those with the standard gene. Their peak blood levels were roughly 1.5 times higher, and overall drug exposure was about 1.6 times greater. People carrying the CYP2C9*13 variant showed very similar increases. Oral clearance of irbesartan was roughly 40 to 44 percent lower in both variant groups compared to the standard genotype.
6PubMed. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjectsPharmacokinetic modeling work has confirmed these patterns, predicting that overall drug exposure in people with these variants is about 1.5 to 1.6 times higher than in people with the standard genotype.
7PubMed. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypesWhat this means practically: if you carry one of these slower-metabolizer variants, a single dose of irbesartan stays at higher levels for longer. Instead of a 15-hour half-life at the upper end of normal, you might see something closer to 20 hours or more. After five half-lives, that pushes complete clearance from about three days to closer to four. Most prescribers don’t routinely test for CYP2C9 genotype before starting irbesartan, because the drug has a wide safety margin. But if you’ve been told you’re a “poor metabolizer” for CYP2C9 based on previous pharmacogenomic testing, it’s worth mentioning to your doctor.
Age, Kidney Disease, and Other Individual Factors
Older adults handle irbesartan a bit differently than younger ones. A pharmacokinetic study comparing young and elderly subjects found that overall drug exposure (measured by area under the curve) was about 43 percent higher in elderly participants, and peak concentration was about 49 percent higher. The drug also reached its peak slightly faster in older subjects. However, the researchers concluded that no dose adjustment was needed based on age, because irbesartan’s safety profile remained acceptable across both groups.
8PubMed Central. The effects of age and gender on the pharmacokinetics of irbesartanSex made no meaningful difference. Peak levels, total exposure, and elimination half-life were all statistically similar between men and women in the same study. Elderly women did show a small reduction in the amount of unchanged irbesartan cleared through the kidneys, but since less than 3 percent of the drug is excreted that way, this had no practical impact.
8PubMed Central. The effects of age and gender on the pharmacokinetics of irbesartanKidney disease is where the story gets interesting. You might expect that people with impaired kidney function would clear irbesartan more slowly, but that’s not what happens. A study across multiple levels of kidney impairment, including people on hemodialysis, found no meaningful relationship between kidney function and any major pharmacokinetic measurement. There was no extra accumulation with repeated dosing, and hemodialysis did not remove irbesartan from the blood. The drug simply isn’t cleared through the kidneys in any significant amount, so even severe renal impairment doesn’t change how long it stays in your system.
9PubMed. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysisFor children and adolescents, pharmacokinetic studies found that blood-level profiles looked similar to those in adults when the dose was adjusted for body weight (around 2 mg/kg). There was no notable difference between the 6-to-12-year and 13-to-16-year age groups.
10PubMed. The pharmacokinetics of irbesartan in hypertensive children and adolescentsDrug Interactions That Slow Clearance
Since CYP2C9 is the bottleneck, anything that inhibits this enzyme can extend irbesartan’s stay in the body. A review of interactions among angiotensin receptor blockers noted that while CYP-mediated drug interactions with irbesartan are generally modest in clinical practice, they aren’t zero.
11Current Drug Metabolism. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450Animal and in-vitro studies have demonstrated the principle clearly. In one study in rats, co-administration with succinic acid (a compound found in some fermented foods and supplements) increased irbesartan’s overall exposure by about 60 percent and stretched the half-life from roughly 13 hours to about 21 hours. The mechanism: succinic acid inhibited CYP2C9 activity.
12PubMed Central. Pharmacokinetic study on the interaction between succinic acid and irbesartan in rats and its potential mechanismA similar pattern appeared with danshensu, a compound derived from a traditional Chinese medicinal herb. In rats, danshensu roughly doubled irbesartan’s peak blood level and increased total drug exposure by about 70 percent, again by suppressing CYP2C9.
13PubMed. Drug-drug interaction between danshensu and irbesartan and its potential mechanismThese are animal studies, so the exact numbers don’t translate directly to humans. But the underlying mechanism is the same one operating in people: if something else is tying up CYP2C9, irbesartan clears more slowly. Commonly prescribed drugs known to inhibit CYP2C9 include fluconazole (an antifungal), amiodarone (a heart rhythm drug), and fluoxetine. If you’re taking any of these alongside irbesartan, the effective half-life could be longer than the standard 11-to-15-hour range.
What Happens After You Stop Taking It
When you discontinue irbesartan, blood levels drop according to the half-life just described: roughly halving every 11 to 15 hours and reaching negligible levels within about three days (longer if you’re a slow metabolizer). But the pharmacological effect on blood pressure doesn’t vanish the instant the drug leaves. Irbesartan binds tightly to AT1 receptors and dissociates slowly, so some blood-pressure-lowering effect can persist slightly beyond what drug levels alone would predict.
That said, the effect does fade. Data from a randomized trial comparing three antihypertensives found that after stopping irbesartan 300 mg, systolic blood pressure climbed at a rate of about 3.6 mmHg per day. Within a few days of the last dose, much of the blood-pressure benefit was gone.
14PubMed Central. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramiprilThis has practical implications for missed doses. If you forget a single dose, you’re unlikely to experience a dramatic spike in blood pressure, because some drug is still present from the previous dose. But two or three consecutive missed doses, and you’re essentially running without coverage. There’s no dangerous “rebound hypertension” reported with irbesartan the way there is with some older blood pressure drugs like clonidine, but your pressure will simply drift back to its untreated level within a few days.
How Irbesartan Compares to Other ARBs
If you’ve switched from another angiotensin receptor blocker or are considering one, it helps to know where irbesartan falls in the family. ARBs vary widely in how long they persist in the body. Losartan has the shortest half-life at roughly 2 hours (though its active metabolite lasts longer). Valsartan sits around 6 hours. Irbesartan falls in a middle-to-long range at 11 hours or more. Telmisartan is the longest-lasting at about 24 hours.
15PubMed Central. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients16Journal of Human Hypertension. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
These differences matter most when adherence isn’t perfect. A drug with a longer half-life is more forgiving of a late or missed dose, because blood levels haven’t dropped as far before the next pill arrives. Irbesartan’s half-life is long enough to support once-daily dosing comfortably. It’s also long enough that if you take your dose 4 or 5 hours late, the gap in coverage is modest. Losartan, by contrast, depends heavily on its active metabolite to maintain round-the-clock effect, and valsartan’s shorter duration means a missed dose is felt sooner.
Lab Detection of Irbesartan
Irbesartan doesn’t appear on standard workplace drug panels, which test for recreational drugs and controlled substances. But if you’re involved in a pharmacokinetic study, a clinical trial, or a medical situation where precise drug levels matter, irbesartan can be measured in both blood plasma and urine. Validated high-performance liquid chromatography assays can detect the drug down to concentrations of 1 nanogram per milliliter in both matrices.
17PubMed. High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urineFrom a stability standpoint, irbesartan remains intact in frozen plasma and urine samples for at least seven months at minus 20 degrees Celsius, which is useful for clinical trials that bank samples for later analysis but also tells you something about the molecule’s chemical robustness. In a living body running at 37 degrees with active enzymes chewing through it, the drug breaks down much faster, but the stability data underscore that irbesartan doesn’t spontaneously degrade in biological fluids the way some less stable compounds do.
17PubMed. High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urinePutting the Numbers Together
For someone with normal liver function, standard CYP2C9 genetics, and no interacting medications, a single dose of irbesartan will peak in about one and a half to two hours and then decline with a half-life of 11 to 15 hours.
18Journal of the Brazilian Chemical Society. Voltammetry of irbesartan drug in pharmaceutical formulations and human blood: quantification and pharmacokinetic studies After five half-lives, somewhere between 55 and 75 hours, trace amounts will still be detectable on sensitive lab equipment but the concentration will be below 5 percent of the peak. For all practical purposes, the drug is gone from your body in about two and a half to three days after your last dose.
If you carry a CYP2C9 slow-metabolizer variant, add roughly a day to that window. If you’re taking a strong CYP2C9 inhibitor like fluconazole, the extension could be even greater. Kidney disease, age, sex, and food intake do not meaningfully alter the timeline. And if you’re on chronic daily dosing, the relevant question isn’t really “how long does one dose last” but rather “how quickly does the drug wash out after I stop.” The answer there is also about three days to reach steady-state-free levels, mirroring the three days it takes to build up to steady state when you start.